Eular 2019: Biogen to present new safety and Efficacy Data on Biosmiliars


Biogen’s three biosimilar treatments – BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab) – are estimated to save the European healthcare system 1.8 billion euros in 2019

CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that it will present new data at the European Congress of Rheumatology (EULAR) 2019 in Madrid, Spain (June 12-15). The abstracts include real-world data from the company’s biosimilar anti-TNF portfolio, which includes BENEPALI™ (etanercept), FLIXABI™ (infliximab) and IMRALDI™ (adalimumab). Biosimilars are products that are demonstrated to be similar to or interchangeable with approved biological product and have the potential to lower drug costs. In Europe, approximately 145,000 patients have been treated with a Biogen biosimilar and the company expects the uptake of these products to generate 1.8 billion euros in healthcare cost savings in 2019.

“Patients with chronic inflammatory diseases face the reality of a lifetime of ongoing disease management and now biosimilars enable more patients access to those life-changing medicines while providing our healthcare systems significant savings,” said Dr. Peter Taylor, Norman Collisson professor of musculoskeletal sciences, Nuffield department of orthopedics, rheumatology and musculoskeletal sciences at the University of Oxford, England. “The new real-world data to be presented at EULAR further establish the comparable safety and efficacy of biosimilars against their reference products.”

#rheumatoid arthritis

Publisert av


Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg

4 tankar om “Eular 2019: Biogen to present new safety and Efficacy Data on Biosmiliars”

  1. You are welcome to share your experience with the Biosmiliars here. Is the cost-effectiveness really better. What about patients who have a severe form of RA? From Liz we know, Biosmiliars can not take all rheumatic folks. They are not identical to the original product!

  2. Thank you Jan for the discussion. It may be, that the cheaper preparations RA patients benefit better effect as older patients. Patients like Liz and I, who have an aggressive history of RA for more than 50 years, are not well advised to use biosmiliars.
    Rheumatologists meanwhile say. Older rheumatic patients with aggressive forms are often unsuitable for this type of therapy. Newer therapies are unsuitable, read here.
    We are the forgotten patients in research.

  3. The replicas are definitely not for people who have already been treated with the original product. Saving on rheumatics is the wrong way. The costs of a combined therapy then increases the cost again.

    1. Der er ikke fundet nye sikkerhedsproblemer ved de biologiske og biosimilære lægemidler, som er underlagt skærpet indberetningspligt. Det viser en ny rapport, som Lægemiddelstyrelsen netop har offentliggjort.

Innlegget er stengt for innspel.